regulation is the sole category represented across all 2 tracked stories. American Lung Association is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 8 original sources per story, versus 3.2 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about U.S. Food and Drug Administration
regulation is the sole category represented across all 2 tracked stories. American Lung Association is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 8 original sources per story, versus 3.2 across the same-window beat baseline. The 126-day window averages about 0.1 stories each week. Their average consequence score of 6.5 sits level with the 6.5 recorded across the beat in that window. U.S. Food and Drug Administration appears in 2 tracked Legal stories published from February 23, 2026 through June 28, 2026.
Stories tracked
2
Per week
0.1
Sources per story
8
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1418 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering U.S. Food and Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
The 2025 National Youth Tobacco Survey reports a record low but persistent 5.2% youth e-cig use, intensifying American Lung Association demands for FDA to reverse its flavored vape authorizations. This regulatory reversal could spawn new administrative law challenges and test the scope of FDA’s tobacco authority, especially given the nearly 90% flavor preference among underage users. Legal experts weigh the viability of forced authorization revocations against public health considerations.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
U.S. Food and Drug Administration is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
